GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (NAS:BIIB) » Definitions » Asset Turnover

Biogen (Biogen) Asset Turnover : 0.09 (As of Mar. 2024)


View and export this data going back to 1991. Start your Free Trial

What is Biogen Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Biogen's Revenue for the three months ended in Mar. 2024 was $2,291 Mil. Biogen's Total Assets for the quarter that ended in Mar. 2024 was $26,706 Mil. Therefore, Biogen's Asset Turnover for the quarter that ended in Mar. 2024 was 0.09.

Asset Turnover is linked to ROE % through Du Pont Formula. Biogen's annualized ROE % for the quarter that ended in Mar. 2024 was 10.49%. It is also linked to ROA % through Du Pont Formula. Biogen's annualized ROA % for the quarter that ended in Mar. 2024 was 5.89%.


Biogen Asset Turnover Historical Data

The historical data trend for Biogen's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Asset Turnover Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.55 0.52 0.45 0.42 0.38

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.10 0.10 0.10 0.09 0.09

Competitive Comparison of Biogen's Asset Turnover

For the Drug Manufacturers - General subindustry, Biogen's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biogen's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biogen's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Biogen's Asset Turnover falls into.



Biogen Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Biogen's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=9835.6/( (24554.1+26844.8)/ 2 )
=9835.6/25699.45
=0.38

Biogen's Asset Turnover for the quarter that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Mar. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Mar. 2024 ))/ count )
=2290.5/( (26844.8+26567.6)/ 2 )
=2290.5/26706.2
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Biogen  (NAS:BIIB) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Biogen's annulized ROE % for the quarter that ended in Mar. 2024 is

ROE %**(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=1573.6/15006.2
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(1573.6 / 9162)*(9162 / 26706.2)*(26706.2/ 15006.2)
=Net Margin %*Asset Turnover*Equity Multiplier
=17.18 %*0.3431*1.7797
=ROA %*Equity Multiplier
=5.89 %*1.7797
=10.49 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Biogen's annulized ROA % for the quarter that ended in Mar. 2024 is

ROA %(Q: Mar. 2024 )
=Net Income/Total Assets
=1573.6/26706.2
=(Net Income / Revenue)*(Revenue / Total Assets)
=(1573.6 / 9162)*(9162 / 26706.2)
=Net Margin %*Asset Turnover
=17.18 %*0.3431
=5.89 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Biogen Asset Turnover Related Terms

Thank you for viewing the detailed overview of Biogen's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (Biogen) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
Executives
Priya Singhal officer: Head of Development C/O ZAFGEN, INC., 175 PORTLAND STREET 4TH FL, BOSTON MA 02114
Jane Grogan officer: Head of Research BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Susan Langer director BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Ginger Gregory officer: EVP, Human Resources C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Adam Keeney officer: Head of Corporate Development BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Christopher Viehbacher director, officer: President and CEO C/O AXCELLA HEALTH, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Susan H Alexander officer: EVP, General Counsel C/O BIOGEN IDEC INC., 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Nicole Murphy officer: Head of Pharm Ops and Tech BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Rachid Izzar officer: Head of Alzheimer's Disease BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142
Chirfi Guindo officer: EVP Glob. Mkt Acc & Cust Innov C/O BIOGEN INC., 225 BINNEY ST., CAMBRIDGE MA 02142
Alfred Sandrock officer: Grp SVP, Chief Medical Officer 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Brian S Posner director 14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Jones William D /ca/ director
Maria C Freire director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Jesus B Mantas director BIOGEN INC., 225 BINNEY STREET, CAMBRIDGE MA 02142

Biogen (Biogen) Headlines